Related Experiment Video
Updated: May 6, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients
Chi Hoon Maeng1, Ho Yun Lee, Young Wook Kim
1Division of Pulmonary and Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, South Korea. sangwon72.um@samsung.com.
Background:
Despite the key role of mutational analysis in targeted therapy, the difficulty in acquisition of adequate tumor tissues for molecular genotyping in advanced non-small cell lung cancer (NSCLC) has led to the need for a fast and efficient method for detecting genetic alterations for targeted therapy.
Patients And Methods:
We analyzed tissue specimens of advanced NSCLC. A mass spectrometry-based assay was used to investigate 471 oncogenic mutations. All tumor specimens were prepared from fresh-frozen tissues.
Results:
In total, there were 59 hotspot mutations in 67% of the entire patient group (41 out of 61 patients). The most frequent mutation was in TP53 (n=24, 39.3%), followed by EFGR (n=19, 31.1%). Others included MLH1, KRAS, PIK3CA, ERBB2, ABL1 and HRAS.
Conclusion:
Our results suggest that molecular genotyping using high-throughput technology such as OncoMap v4 is feasible, even with small biopsied specimens from patients with advanced NSCLC.
Insights
Molecular genotyping in advanced non-small cell lung cancer (NSCLC) is feasible with high-throughput assays. This method efficiently detects oncogenic mutations, even from small tumor biopsy samples, aiding targeted therapy decisions.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Accurate molecular genotyping is crucial for targeted therapy in advanced non-small cell lung cancer (NSCLC).
- Limited tumor tissue acquisition poses a challenge for comprehensive genetic analysis in advanced NSCLC patients.
Purpose of the Study:
- To evaluate the feasibility of a high-throughput mass spectrometry-based assay for detecting genetic alterations in advanced NSCLC.
- To assess the efficiency of molecular genotyping using limited tumor specimens for guiding targeted therapy.
Main Methods:
- Analysis of tissue specimens from advanced NSCLC patients.
- Utilized a mass spectrometry-based assay (OncoMap v4) to investigate 471 oncogenic mutations.
- Specimens were prepared from fresh-frozen tissues.
Main Results:
- Identified 59 hotspot mutations in 67% of patients (41 out of 61).
- TP53 mutations were most frequent (39.3%), followed by EGFR mutations (31.1%).
- Other detected mutations included MLH1, KRAS, PIK3CA, ERBB2, ABL1, and HRAS.
Conclusions:
- High-throughput molecular genotyping is feasible for advanced NSCLC, even with small biopsy samples.
- This approach facilitates rapid detection of actionable genetic alterations for personalized treatment strategies.
